New significant data for Campath in MS

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

New significant data for Campath in MS

Postby MSUK » Wed Apr 14, 2010 9:08 am

Significant percentage of MS patients receiving Alemtuzumab in Genzyme's phase 2 trial remain free of clinically-active disease - ... ageid/1307
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Postby dignan » Wed Apr 14, 2010 1:26 pm

Here is the abstract from the AAN meeting on these very encouraging results:

Alemtuzumab Reduces Disease Progression in RRMS: Long-Term Results of the CAMMS223 Trial

Omar Khan, Detroit, MI, N. A. on Behalf of the CAMMS223 Study Group

OBJECTIVE: To assess clinically disease-free status and safety of alemtuzumab-treated MS patients at 4 years follow-up.

BACKGROUND: Alemtuzumab demonstrated efficacy superior to subcutaneous IFNB-1a in a 3-year, phase 2 trial with relapsing-remitting MS (RRMS) patients, significantly reducing the relapse rate and risk for sustained accumulation of disability (SAD) (all comparisons p<0.001). Clinically disease-free was defined as the absence of both relapses and SAD. The proportion of clinically diseasefree patients was significantly higher for alemtuzumab compared with IFNB-1a at years 1, 2 and 3 (all pvalues < 0.0001).

DESIGN/METHODS: 334 early, active RRMS patients were randomized 1:1:1 to IFNB-1a (44mcg SC 3x/week), 24 mg or 12 mg/day alemtuzumab IV administered during 2 or 3 brief annual cycles. No alemtuzumab was administered after 24 months. IFNB-1a was administered through 36 months. Post hoc analyses of 4-year patient follow-up compared treatment groups on the proportion of relapse-free, 6 month SAD-free, and clinically diseasefree patients. Additional safety data were analyzed.

RESULTS: At year 4, 77% of alemtuzumab-treated patients were relapsefree compared to 49% of IFNB-1a-treated patients; 91% of alemtuzumab patients were SAD-free vs. 68% of IFNB-1a patients (p<0.001). 71% of alemtuzumab patients were clinically disease-free v. 35% for IFNB-1a at year 4 (p<0.001). Similar results were observed when restricting analyses to patients receiving only 2 cycles of alemtuzumab. Updated safety results will also be reported.

CONCLUSIONS/RELEVANCE: Alemtuzumab-treated patients maintained a clinically disease-free status in greater proportions than IFNB-1a-treated patients at year 4. These data support the ability of alemtuzumab to achieve clinically disease-free status and to halt clinical progression in the vast majority of RRMS patients receiving alemtuzumab. This treatment effect at year 4 is observed even for those patients who completed 2 annual cycles of alemtuzumab during the first 12 months. ... 0L_P04.213
User avatar
Family Elder
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Postby mendesnelson » Mon Apr 19, 2010 11:18 pm

I just posted the official company release of this information! These are some pretty amazing numbers never before seen for any MS treatment. I'm really shocked that NO ONE has posted any replies to your post yet. I was in the original cohort Campath study and received two infusions of Campath and have been untreated since my last infusion in 2005. So far so good its been five years and minimal progression - if any. I was one of the few that developed Graves Disease at month 23. Treating that with Methimazole pills.
User avatar
Posts: 8
Joined: Mon Apr 19, 2010 3:00 pm

Return to Campath (Lemtrada, Alemtuzumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service